Affiliation: Stanford University
- Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testisKelly Morgan
Department of Urology, Stanford University School of Medicine and Palo Alto Veterans Affairs Medical Center, Stanford, California, USA
Urology 64:808-9. 2004..An incidentally discovered testicular mass in a man with high-grade, invasive bladder cancer should be considered a metastatic lesion until proven otherwise...
- Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancerDavid Feldman
Department of Medicine Endocrinology, Stanford University School of Medicine, 300 Pasteur Drive, Room S 025, Stanford, CA 94305 5103, USA
Nutr Rev 65:S113-5. 2007
- Nonplatinum therapy in advanced bladder cancerSandy Srinivas
Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Expert Rev Anticancer Ther 6:887-94. 2006..Conversely, noncisplatin-containing regimens have been shown to have a more favorable toxicity profile and to have activity in advanced bladder cancer. Here, various nonplatinum chemotherapy regimens for advanced disease are reviewed...
- A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinomaSandy Srinivas
Division of Oncology, Stanford University School of Medicine, Stanford, California 94305 1205, USA
Chemotherapy 55:321-6. 2009..We conducted a phase II study to evaluate the efficacy and safety of docetaxel and oxaliplatin in metastatic urothelial cancer patients who had received prior platinum therapy...
- A phase II trial of calcitriol and naproxen in recurrent prostate cancerSandy Srinivas
Stanford University School of Medicine, Stanford, CA 94305, USA
Anticancer Res 29:3605-10. 2009..The objective of the study was to determine whether treatment with calcitriol and naproxen is effective in safely delaying the growth and progression of PCa in men with early recurrent disease...
- Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancerSandy Srinivas
Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
Urology 67:1001-6. 2006..To assess the effect of triamcinolone administration on the serum prostate-specific antigen (PSA) response and the time to progression in patients with androgen-independent prostate cancer (AIPC)...
- Bone related events in high risk prostate cancerSandy Srinivas
Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
J Urol 176:S50-4. 2006..We provide recommendations for defining and treating bone related events in high risk prostate cancer...
- A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinomaSandy Srinivas
Division of Oncology, Stanford Medical Center, Stanford, CA, USA
BJU Int 96:536-9. 2005....
- A nonplatinum combination in metastatic transitional cell carcinomaSandy Srinivas
Stanford University Medical Center, Stanford, California, USA
Am J Clin Oncol 28:114-8. 2005..The objective of this research was to determine if a combination of paclitaxel and gemcitabine would be effective in patients who were unable to receive cisplatin or have failed cisplatin treatment...
- The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answerLauren C Harshman
Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
Am J Clin Oncol 31:417-23. 2008..We conducted a phase II trial to determine the efficacy and safety of the combination of thalidomide and capecitabine in mRCC...
- Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinomaLauren C Harshman
Stanford University School of Medicine, California 94305, USA
Cancer Invest 27:851-6. 2009..2 months with rises > 15%. This study identifies increased hemoglobin as a possible consequence of VEGF inhibitors. The correlation with longer PFS suggests that rise in hemoglobin may be a surrogate biomarker of efficacy...
- Toxicities of targeted agents in advanced renal cell carcinomaPriti Patel
Stanford University, Stanford, CA 94305, USA
Curr Clin Pharmacol 6:181-8. 2011..The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management...
- Current status of cytoreductive nephrectomy in metastatic renal cell carcinomaLauren C Harshman
Fellow, Medical Oncology, Stanford University School of Medicine, Division of Medical Oncology, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Expert Rev Anticancer Ther 7:1749-61. 2007....
- Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patientsLauren C Harshman
Division of Oncology and Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
BJU Int 106:1805-11. 2010..RRM1 is the primary cellular target of gemcitabine and previous studies in resected early-stage lung cancer have shown a survival benefit for patients with high expression...
- Positron emission tomography in the initial staging of esophageal cancerSherry M Wren
Department of Surgery, Palo Alto Veterans Hospital, 3801 Miranda Ave, Palo Alto, CA 94304, USA
Arch Surg 137:1001-6; discussion 1006-7. 2002..To assess the value of positron emission tomography (PET) compared with computed tomography (CT) in the initial staging of esophageal cancer...
- Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)Lauren C Harshman
Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
Urol Oncol 31:379-85. 2013..Tyrosine kinase inhibitors (TKI) have dramatically changed the management paradigm of advanced renal cell carcinoma (RCC) and are increasingly being used preoperatively to achieve cytoreduction...
- Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
Lancet Oncol 13:927-35. 2012..We assessed the use of conditional survival--a measure that accounts for elapsed time since treatment initiation--for prognostication in patients with metastatic renal-cell carcinoma treated with first-line VEGF-targeted therapies...
- Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinibLauren C Harshman
Division of Oncology, Stanford University Medical Center, CA 94305, USA
Nat Rev Urol 6:338-43. 2009..A 57-year-old woman presented to the emergency department at a community hospital with a 2-month history of fatigue and right-sided flank and abdominal pain. Noncontrast CT of the abdomen and pelvis revealed a 9.1 cm right renal mass...
- Variations in normal serum alpha-fetoprotein (AFP) levels in patients with testicular cancer on surveillancePriti Patel
Division of Medical Oncology, Stanford University, CA 94305, USA
Onkologie 35:588-91. 2012..Marked variations occur after serum AFP levels normalize, creating anxiety among patients and physicians during surveillance...
- Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatmentJoanna Badger
Stanford Medical Center, Stanford, CA, USA
J Clin Oncol 23:7224-5. 2005
- A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinomaLauren C Harshman
Stanford Cancer Institute, Division of Oncology, Stanford School of Medicine, Stanford, CA, USA
Clin Genitourin Cancer 11:100-6. 2013....
- Reliability of small amounts of cancer in prostate biopsies to reveal pathologic gradeChristopher R King
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305 5847, USA
Urology 67:1229-34. 2006..Prostate biopsy findings are known to undergrade prostate cancer compared with the pathologic specimens yet remain the only grade guiding disease management...
- The bevacizumab experience in advanced renal cell carcinomaLauren C Harshman
Division of Oncology, Stanford University School of Medicine, Stanford, California, USA
Onco Targets Ther 3:179-89. 2010..With multiple agents now available for the treatment of advanced RCC, identification of patient and tumor-specific biomarkers to inform our choice of first-line therapy and the proper sequence of subsequent therapies is imperative...
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerRonald M Bukowski
Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Clin Oncol 25:4536-41. 2007....
- Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinomaEric Jonasch
Department of Genitourinary Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer 113:72-7. 2008..The purpose of the current study was to evaluate the activity and safety of TLF in patients with refractory metastatic renal cell carcinoma (RCC)...
- Acute pancreatitis associated with sorafenibMingqing Li
Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, USA
South Med J 100:909-11. 2007..Patients should be informed of this rare but potentially serious adverse effect before initiation of sorafenib therapy. Early recognition of this complication and complete discontinuation of sorafenib are recommended...
- Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapyI Jenna Liu
Section of Urology, Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif, USA
Urol Int 77:69-75. 2006..This study was designed to determine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in the evaluation of metastatic transitional cell carcinoma (TCC)...
- Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg dailyJeremiah C Murphy
Section of Urology, Medical College of Georgia, Augusta, 30912, USA
J Androl 25:630-4. 2004..047). Flutamide at 500 mg did not result in significant changes in testosterone, PSA, prostate volume, or androgen deficiency symptoms compared to 750 mg daily after 3 months...